{
    "clinical_study": {
        "@rank": "77172", 
        "arm_group": {
            "arm_group_label": "Single Arm", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Whether low-dose radiation in addition to Taxotere and Erbitux improves the response rate of\n      patients with recurrent unresectable head and neck squamous cell carcinoma."
        }, 
        "brief_title": "Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma", 
        "condition": [
            "Squamous Cell Carcinoma", 
            "Head and Neck", 
            "Recurrent Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Head and Neck Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigator's approach is based on the following reasons:\n\n        -  Low dose hyper-radiation sensitivity response will be significantly enhanced in\n           Taxotere- induced G2/M cell cycle arrest.\n\n        -  LDFRT will render enhanced bax activation mediated mode of cell death.\n\n        -  Erbitux will arrest the cells in G1/G0 phase leading to p21-mediated mode of cell\n           death.\n\n        -  The toxicity profile is expected to be minimal.\n\n      Based on the above mentioned reasons, we propose this novel schema of treatment in recurrent\n      SCCHN."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have pathologically confirmed recurrence (reappearance of previously\n             cleared) squamous cell cancer primary in the upper aerodigestive tract .Patients may\n             have experienced more than one recurrence as long as the first recurrence occurred \u2265\n             6 months following the end of the prior RT.\n\n          -  The recurrence must have defined bi- or uni-dimensional measurements.\n\n          -  Recurrence must be confined to the head and neck above the clavicles (loco-regional\n             recurrence).\n\n          -  The patient must not be a candidate for surgical resection.\n\n          -  Patients must be at least 6 months from completion of prior chemotherapy and\n             radiation therapy.\n\n          -  Patients may have received prior chemotherapy as a component of their primary\n             treatment, but not for recurrent disease.\n\n          -  ECOG performance status 0-2.\n\n          -  Granulocytes >= 1500/mm3, platelets >= 100,000/mm3, serum bilirubin =< 1.5 mg/dl,\n             creatinine < 1.5 mg/dl within 3 weeks prior to registration.\n\n          -  LFT's \u2264 2 x normal (SGOT/SGPT/Alkaline Phosphatase).If > 2 x normal, liver ultrasound\n             or CT is required to exclude metastases. If negative for metastases, patients are\n             eligible.\n\n          -  Patients must sign a study-specific informed consent form prior to study entry\n\n        Exclusion Criteria:\n\n          -  Distant metastases outside of the head and neck.\n\n          -  Primary disease in the nasopharynx or the salivary gland.\n\n          -  Other concurrent invasive malignancies.\n\n          -  Prior invasive malignancy unless disease free for at least two years (except prior in\n             situ malignancies, e.g. cervix, breast, non-melatomatous skin cancer, etc. are\n             permissible).\n\n          -  Intercurrent medical illnesses which would impair patient tolerance to therapy or\n             limit survival.\n\n          -  Pre-existing grade \u2265 2 peripheral sensory neuropathy\n\n          -  Pregnant and nursing women are excluded because of the potential teratogenic effects\n             and potential unknown effects on nursing newborns."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01794845", 
            "org_study_id": "UMIAMI-20090467"
        }, 
        "intervention": [
            {
                "arm_group_label": "Single Arm", 
                "description": "Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Mondays.", 
                "intervention_name": "Erbitux", 
                "intervention_type": "Drug", 
                "other_name": "Cetuximab"
            }, 
            {
                "arm_group_label": "Single Arm", 
                "description": "Taxotere : 20 mg/m2  IV once a week on Mondays on weeks 2 to 7 in 500 cc \u00bd normal saline solution (NSS) or D5W over 60 minutes. Additional intravenous fluids pre- or post-Taxotere can be administered as necessary.", 
                "intervention_name": "Taxotere", 
                "intervention_type": "Drug", 
                "other_name": "Docetaxel"
            }, 
            {
                "arm_group_label": "Single Arm", 
                "description": "Low-dose fractionated Radiation (LDFRT): 0.5 Gy per fraction BID at least 6 hours apart on Tuesday and Wednesday of weeks 2 to 7 for a total dose of 12 Gy.", 
                "intervention_name": "Low Dose Fractionated Radiation Therapy", 
                "intervention_type": "Radiation", 
                "other_name": "LDFRT"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Cetuximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "SCCHN", 
            "Head and Neck Cancer", 
            "Squamous Cell Carcinoma", 
            "Recurrent"
        ], 
        "lastchanged_date": "February 28, 2014", 
        "location": {
            "contact": {
                "email": "mabramowitz@med.miami.edu", 
                "last_name": "Matthew C Abramowitz, MD", 
                "phone": "305-243-4200"
            }, 
            "contact_backup": {
                "email": "sylvester@emergingmed.com", 
                "last_name": "University of Miami Sylvester Comprehensive Cancer Center", 
                "phone": "866-574-5124"
            }, 
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33136"
                }, 
                "name": "University of Miami Sylvester Comprehensive Cancer Center"
            }, 
            "investigator": [
                {
                    "last_name": "Arnold Markoe, ScD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Chukwuemeka Ikpeazu, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Donald Weed, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Elizabeth Franzmann, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Khaled Tolba, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Aaron Wolfson, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michael Samuels, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Nagy Elsayyad, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Laura Freedman, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Gustavo Fernandez, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma", 
        "overall_official": {
            "affiliation": "University of Miami Sylvester Comprehensive Cancer Center", 
            "last_name": "Matthew C Abramowitz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective is to show improvement of the overall response rate from the current standard of 40% with chemotherapy alone, to 70% with the addition of LDFRT, in patients with recurrent unresectable head and neck squamous cell carcinoma.", 
            "measure": "Overall Response Rate of Participants", 
            "safety_issue": "No", 
            "time_frame": "3.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01794845"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assess the safety profile (acute and late toxicities) of the proposed treatment", 
                "measure": "Number of Participants Experiencing Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "3.5 years"
            }, 
            {
                "measure": "Progression-Free Survival", 
                "safety_issue": "No", 
                "time_frame": "3.5 years"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "3.5 years"
            }
        ], 
        "source": "University of Miami Sylvester Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Miami Sylvester Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}